User login
Key clinical point: Adding abiraterone acetate plus prednisone (AA+P) to androgen deprivation therapy (ADT) extends survival in patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) and visceral disease.
Major finding: AA+P vs placebo significantly improved overall survival (median, 55.4 months vs 33.0 months; hazard ratio [HR], 0.582; P = .0029) and radiographic progression-free survival (median, 30.7 months vs 18.3 months; HR, 0.527; P = .0005) in patients with vs without visceral metastases.
Study details: A post hoc analysis of LATITUDE study including 1,199 newly diagnosed patients with mCSPC who were randomly assigned to AA+P and ADT or placebo plus ADT.
Disclosures: This work was funded by Janssen Research & Development. The authors reported employment/stock ownership; received personal/advisory fees, funding, honorarium, and travel and accommodation expense outside this work; were employees of Janssen Research & Development; and/or held company stock.
Source: Baciarello G et al. Eur J Cancer. 2021 Dec 22. doi: 10.1016/j.ejca.2021.11.026.
Key clinical point: Adding abiraterone acetate plus prednisone (AA+P) to androgen deprivation therapy (ADT) extends survival in patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) and visceral disease.
Major finding: AA+P vs placebo significantly improved overall survival (median, 55.4 months vs 33.0 months; hazard ratio [HR], 0.582; P = .0029) and radiographic progression-free survival (median, 30.7 months vs 18.3 months; HR, 0.527; P = .0005) in patients with vs without visceral metastases.
Study details: A post hoc analysis of LATITUDE study including 1,199 newly diagnosed patients with mCSPC who were randomly assigned to AA+P and ADT or placebo plus ADT.
Disclosures: This work was funded by Janssen Research & Development. The authors reported employment/stock ownership; received personal/advisory fees, funding, honorarium, and travel and accommodation expense outside this work; were employees of Janssen Research & Development; and/or held company stock.
Source: Baciarello G et al. Eur J Cancer. 2021 Dec 22. doi: 10.1016/j.ejca.2021.11.026.
Key clinical point: Adding abiraterone acetate plus prednisone (AA+P) to androgen deprivation therapy (ADT) extends survival in patients with newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC) and visceral disease.
Major finding: AA+P vs placebo significantly improved overall survival (median, 55.4 months vs 33.0 months; hazard ratio [HR], 0.582; P = .0029) and radiographic progression-free survival (median, 30.7 months vs 18.3 months; HR, 0.527; P = .0005) in patients with vs without visceral metastases.
Study details: A post hoc analysis of LATITUDE study including 1,199 newly diagnosed patients with mCSPC who were randomly assigned to AA+P and ADT or placebo plus ADT.
Disclosures: This work was funded by Janssen Research & Development. The authors reported employment/stock ownership; received personal/advisory fees, funding, honorarium, and travel and accommodation expense outside this work; were employees of Janssen Research & Development; and/or held company stock.
Source: Baciarello G et al. Eur J Cancer. 2021 Dec 22. doi: 10.1016/j.ejca.2021.11.026.